Comparative Study of the Characteristics of Sensory and Motor Block Duration of Analgesia Between Intrathecal Hyperbaric Ropivacaine (0.75%) and hyperbaric levobupivacaine (0.5%) Along with 2mg Nalbuphine as an Adjuvant in Patients Undergoing Elective Caesarean Section: A Randomized Controlled Study

This study is a prospective, randomized, double-blind controlled clinical trial designed to compare the characteristics of sensory and motor block produced by intrathecal hyperbaric ropivacaine (0.75%) and hyperbaric levobupivacaine (0.5%), both combined with 2 mg nalbuphine as an adjuvant, in patients undergoing elective caesarean section.

A total of 30 ASA II–III parturients aged 18–40 years scheduled for elective caesarean section under spinal anaesthesia will be enrolled and randomly allocated into two equal groups. Group R will receive 1.8 ml hyperbaric ropivacaine (0.75%) with 2 mg nalbuphine, while Group L will receive 1.8 ml hyperbaric levobupivacaine (0.5%) with 2 mg nalbuphine.

The primary outcome is to compare the onset of sensory and motor block between the two groups. Secondary outcomes include duration of postoperative analgesia, two-segment sensory regression time, intraoperative hemodynamic changes, and incidence of adverse effects such as hypotension, bradycardia, nausea, vomiting, pruritus, shivering, and respiratory depression.

The study aims to identify an intrathecal drug combination that provides effective anaesthesia, stable maternal hemodynamics, adequate postoperative analgesia, and early recovery in patients undergoing elective caesarean section